Edwards Lifesciences exec sells 31,800 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Edwards Lifesciences Corp (EW) executive Daveen Chopra, CVP, TMTT, Surgical & IHFM, exercised 31,800 Employee Stock Options for Common Stock at an exercise price of $72.68 per share and simultaneously sold 31,800 shares of Common Stock on 2026-08-26 in open-market transactions. The sales comprised 1,154 shares at a weighted average price of $91.7614 (individual trades ranged from $91.660 to $91.975) and 30,646 shares at a weighted average price of $90.9922 (trades ranged from $90.645 to $91.640). The option, originally exercisable since 2021-05-07 and expiring on 2027-05-06, now shows 0 options remaining in this grant.
Insider Trade Summary
Exercise and Sale: 31,800 shares ($583K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Chopra Daveen
Role
CVP, TMTT, Surgical & IHFM
Sold
31,800 shs ($2.89M)
Approx. gross sale proceeds
$2.89M
Approx. exercise cost
$2.31M
Approx. pre-tax spread
$583K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Acquire) | 31,800 | $0.00 | $0.00 |
| Exercise | Common Stock | 31,800 | $72.68 | $2.31M |
| Sale | Common Stock F1 | 1,154 | $91.7614 | $106K |
| Sale | Common Stock F2 | 30,646 | $90.9922 | $2.79M |
Holdings After Transaction:
Employee Stock Option (Right to Acquire) — 0 contracts (Direct);
Common Stock — 44,324 shares (Direct)
Footnotes (2)
- F1. This transaction was executed in multiple trades at prices ranging from $91.660 to $91.975. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- F2. This transaction was executed in multiple trades at prices ranging from $90.645 to $91.640. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 31,800 shares
Option exercise price: $72.68 per share
Shares sold (block 1): 1,154 shares
+5 more
8 metrics
Options exercised
31,800 shares
Employee Stock Option (Right to Acquire) exercised into Common Stock on 2026-08-26
Option exercise price
$72.68 per share
Exercise price of Employee Stock Option originally exercisable 2021-05-07, expiring 2027-05-06
Shares sold (block 1)
1,154 shares
Common Stock sale on 2026-08-26 at weighted average price $91.7614
Weighted average sale price (block 1)
$91.7614 per share
Multiple trades between $91.660 and $91.975 for 1,154 shares
Shares sold (block 2)
30,646 shares
Common Stock sale on 2026-08-26 at weighted average price $90.9922
Weighted average sale price (block 2)
$90.9922 per share
Multiple trades between $90.645 and $91.640 for 30,646 shares
Options remaining from this grant
0 options
Total shares following transaction for the derivative security
Net shares sold
31,800 shares
Transaction summary netBuySellShares across reported buy/sell transactions
Key Terms
Employee Stock Option (Right to Acquire), beneficial ownership, weighted average sale price, derivative security, +1 more
5 terms
Employee Stock Option (Right to Acquire) financial
"security_title: "Employee Stock Option (Right to Acquire)""
beneficial ownership financial
"reflects changes in beneficial ownership only; it does not identify other"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open market or private transaction financial
"transaction_code_description": "Sale in open market or private transaction""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did EW executive Daveen Chopra report on this Form 4?
Daveen Chopra reported exercising 31,800 stock options at $72.68 per share into Common Stock and selling a total of 31,800 shares of Edwards Lifesciences Corp Common Stock in open-market transactions on 2026-08-26.
How many Edwards Lifesciences (EW) options did Daveen Chopra have left from this grant after the transaction?
For the reported Employee Stock Option grant, the filing shows 31,800 options exercised and 0 options remaining following the transaction, as reflected in the total shares following transaction field for that derivative security.
Were Daveen Chopra’s EW transactions made under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is false, and the footnotes do not state that the transactions were made pursuant to a Rule 10b5-1 trading plan.
What role does Daveen Chopra hold at Edwards Lifesciences (EW) according to this Form 4?
According to the Form 4, Daveen Chopra is an officer of Edwards Lifesciences Corp with the title CVP, TMTT, Surgical & IHFM. The reported transactions reflect changes in his beneficial ownership of the company’s securities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
